GlaxoSmithKline Successfully Completes Tender Offer for Shares of Genelabs Technologies, Inc.
07 Enero 2009 - 7:50AM
PR Newswire (US)
LONDON, Jan. 7 /PRNewswire-FirstCall/ -- GlaxoSmithKline plc
(LSE/NYSE: GSK) announced today the successful completion of the
tender offer by its wholly-owned subsidiary Gemstone Acquisition
Corporation for shares of common stock of Genelabs Technologies,
Inc. (NASDAQ:GNLB). The tender offer expired at 12:00 midnight, New
York City time, on Tuesday, January 6, 2009. The depositary for the
tender offer has advised GSK that shareholders of Genelabs have
tendered and not withdrawn a total of approximately 39,250,243
shares of Genelabs common stock. These shares, together with the
shares beneficially owned by GSK and its wholly-owned subsidiaries,
represent approximately 88.55 percent of the outstanding shares of
Genelabs on a fully diluted basis. Gemstone has accepted for
payment all Genelabs shares tendered in the offer. GSK also
announced that Gemstone exercised its "top-up" option in accordance
with the previously announced merger agreement with Genelabs. The
exercise of the top-up option allowed Gemstone to increase its
share ownership percentage of Genelabs through the purchase of
newly-issued shares of Genelabs common stock at the tender offer
price. As a result, Gemstone owns more than 90 percent of the
outstanding shares of Genelabs common stock and intends to effect a
short-form merger as promptly as practicable, without the need for
a meeting of Genelabs shareholders. In the merger, Gemstone will
acquire all other Genelabs shares (other than those as to which
holders properly exercise dissenters' rights) at the same $1.30 per
share price, without interest and less any required withholding
taxes, that was paid in the tender offer. As a result of the
merger, Genelabs will become a wholly-owned subsidiary of GSK and
Genelabs shares will cease to be traded on The NASDAQ Capital
Market. About GlaxoSmithKline plc GlaxoSmithKline plc -- one of the
world's leading research-based pharmaceutical and healthcare
companies -- is committed to improving the quality of human life by
enabling people to do more, feel better and live longer. For
company information including a copy of this announcement and
details of the company's updated product development pipeline,
visit GSK at http://www.gsk.com/. Enquiries: UK Media enquiries:
Philip Thomson (020) 8047 5502 Alice Hunt (020) 8047 5502 Stephen
Rea (020) 8047 5502 US Media enquiries: Nancy Pekarek (919) 483
2839 Mary Anne Rhyne (919) 483 2839 Sarah Alspach (215) 751 7709
Melinda Stubbee (215) 751 7709 European Analyst/Investor enquiries:
David Mawdsley (020) 8047 5564 Sally Ferguson (020) 8047 5543 Gary
Davies (020) 8047 5503 US Analyst/ Investor enquiries: Tom Curry
(215) 751 5419 Jen Hill (215) 751 7002 DATASOURCE: GlaxoSmithKline
plc CONTACT: UK Media: Philip Thomson, Alice Hunt or Stephen Rea,
all at (020) 8047 5502; or US Media: Nancy Pekarek or Mary Anne
Rhyne, both at +1-919-483-2839, or Sarah Alspach or Melinda
Stubbee, both at +1-215-751-7709; or for European Analyst and
Investors: David Mawdsley, (020) 8047-5564, or Sally Ferguson,
(020)-8047-5543, or Gary Davies, (020)-8047- 5503; or for US
Analyst and Investors: Tom Curry, +1-215-751-5419, or Jen Hill,
+1-215-751-7002, all of GlaxoSmithKline plc Web Site:
http://www.gsk.com/
Copyright
Genelabs (NASDAQ:GNLB)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Genelabs (NASDAQ:GNLB)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024
Real-Time news about Genelabs Technologies (MM) (NASDAQ): 0 recent articles
Más de Genelabs Technologies (MM) Artículos de Noticias